根据协议条款，辉瑞将全面负责本次合作的系列临床试验的开展，Summit将提供依沃西用于该系列临床试验；双方共同监督临床研究的进行；同时，双方将各自保留其产品的相关权利。目前依沃西在全球开展临床试验药物均由康方生物生产供应。

Cataract surgery was associated with an increased risk of worsening diabetic retinopathy in adults with type 2 diabetes, ...

2月24日，Summit Therapeutics宣布与辉瑞开展临床试验合作，以评估PD-1/VEGF双特异性抗体Ivonescimab（依沃西单抗，康方生物原研）与辉瑞的多种抗体偶联药物（ADCs）联合用于多种实体瘤的疗效和安全性。

Northwestern University researchers have identified structural features in engineered cell receptors that correlate with ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule ...